Table 2.

Ongoing Selected Clinical Trials for Pancreatic Cancer

NCT	Phase	Treatment	Current Status	Study Group
NCT05251038	I/II	Sotorasib plus systemic chemotherapy	Not yet recruiting	KRAS G12C-mutant advanced pancreatic cancer with progression of disease after first line treatment
NCT05009329	I/II	JAB21822 monotherapy	Recruiting	KRAS G12C-mutant advanced solid tumors
NCT04975256	I/Ib	Adagrasib plus BI 1701963	Active, not recruiting	KRAS G12C-mutant advanced solid tumors
NCT04548752	II	Olaparib plus Pembrolizumab or Olaparib alone	Recruiting	Metastatic pancreatic cancer with germline BRCA1/2 mutations
NCT03948763	I	mRNA-5671/V941 plus Pembrolizumab or mRNA-5671/V941 alone	Active, not recruiting	KRAS mutant advanced or metastatic NSCLC, CRC or Pancreatic Adenocarcinoma
NCT02077881	I/II	Indoximod plus Gemcitabine and Nab-Paclitaxel	Completed	Metastatic pancreatic cancer
NCT04361162	II	Nivolumab plus Ipilimumab and Radiation	Recruiting	Microsatellite stable pancreatic cancer
NCT04543071	II	Cemiplimab and Motixafortide plus systemic chemotherapy	Recruiting	Metastatic treatment naïve pancreatic cancer
NCT02451982	II	Nivolumab, Urelumab, BMS-986253, GVAX and systemic chemotherapy	Recruiting	Surgically resectable pancreatic cancer
NCT03816163	II	Zolbetuximab plus nab-paclitaxel and gemcitabine	Recruiting	CLDN18.2 positive metastatic pancreatic cancer
NCT04111458	I	BI 1701963 plus Trametinib or BI 1701963 alone	Active, not recruiting	Basket trial
NCT03935893	II	Autologous Tumor Infiltrating Lymphocytes	Recruiting	Basket trial
NCT04853017	I	ELI-002; Therapeutic cancer vaccine targeting KRAS	Recruiting	Microsatellite stable pancreatic cancer
NCT03193190	Ib/II	Atezolizumab, Cobimetinib, PEGPH20, Motixafortide, Selicrelumab, Bevacizumab, Simlukafusp alfa, Etrumadenant, Tiragolumab, Tocilizumab and systemic chemotherapy	Recruiting	Metastatic pancreatic cancer